Gilead Sciences Inc Stock Price, News & Analysis

Assembly Biosciences (NASDAQ:ASMB) and Gilead Sciences announced Gilead exercised its option to exclusively license Assembly Bio’s HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366, for recurrent genital herpes on December 22, 2025. Assembly Bio will receive a $35 million payment reflecting an option fee net of prior accelerated funding. Gilead gains sole U.S. development and commercialization rights; Assembly Bio remains eligible for up to $330 million in milestones plus tiered royalties and a U.S. opt-in to share 40% of costs and profits.

Both candidates showed positive Phase 1b antiviral and safety data supportive of once-weekly oral dosing.

Gilead (Nasdaq: GILD) announced a three-year agreement with the U.S. government to lower medicine costs in the U.S. Key terms include discounts on certain medicines in the U.S. Medicaid program, pricing future medicines at parity with other developed nations, and a Direct-to-Patient Program to offer Hepatitis C drug Epclusa at a discounted cash price via TrumpRx.gov. The deal includes a three-year exemption from Section 232 pharmaceutical tariffs tied to further U.S. manufacturing investment. Gilead said the financial impact should be manageable in 2026 and beyond.

The company also confirmed a separate plan to invest $32 billion in U.S. manufacturing, R&D, and infrastructure over five years, projected to generate $43 billion in national economic value and create > 3,000 jobs.

Gilead Sciences (Nasdaq: GILD) announced on December 18, 2025 that Keeley Wettan is appointed Executive Vice President, General Counsel, Legal & Compliance, effective immediately.

Ms. Wettan joins the senior leadership team reporting to Chairman and CEO Daniel O’Day. She has 14 years at Gilead, previously led Global Legal Business Partners, litigation, government investigations, and corporate governance teams, and chairs the Gilead Foundation.

The company highlighted her role supporting launches including lenacapavir and noted Gilead’s 2025 $32 billion U.S. investment plan.

Gilead (Nasdaq: GILD) announced on December 15, 2025 that its investigational single‑tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) met the Phase 3 ARTISTRY‑2 primary endpoint, demonstrating statistical non‑inferiority to BIKTARVY by the FDA snapshot at Week 48. The regimen was generally well tolerated with no new safety signals reported. Top‑line ARTISTRY‑2 results will be combined with ARTISTRY‑1 findings to form the basis for planned regulatory submissions and future scientific presentations. Bictegravir is a guideline‑recommended INSTI; lenacapavir is a first‑in‑class capsid inhibitor with existing approvals for PrEP and multi‑drug‑resistant HIV in multiple countries. The combination remains investigational and is not approved by the U.S. FDA.

Gilead Sciences (Nasdaq:GILD) announced on December 9, 2025 that the Gilead Foundation committed more than $3 million in new grants to support people living with metastatic breast cancer (mBC). The 2025 funding will distribute grants to 53 organizations and support 23 nationwide programs focused on education, care delivery, navigation, mental health, nutrition, and provider training.

The foundation said this builds on more than $21 million in support since 2021 and aims to improve access to breast cancer education and integrated support services across the U.S.

Gilead (Nasdaq: GILD) presented a pooled analysis at ASH 2025 showing consistent safety, efficacy, and quality-of-life benefits for Yescarta (axicabtagene ciloleucel) in relapsed/refractory large B-cell lymphoma (R/R LBCL), including patients ineligible for high-dose chemotherapy and autologous stem cell transplant.

Key pooled outcomes at two years: OS 64.9%, EFS 45.2%, and PFS 47.4%. Three-month complete metabolic response was 55.6%; 12-month duration of response was 61.0%. Safety pooled grade ≥3 TEAEs were 90.5%, with grade ≥3 neurologic events at 19.8%. Quality-of-life measures declined early then improved by Month 12 and Month 24.

Kite (Nasdaq: GILD) and Arcellx reported updated pivotal iMMagine-1 Phase 2 data for investigational anitocabtagene autoleucel (anito-cel) at ASH 2025 with a cutoff of Oct 7, 2025 and median follow-up of 15.9 months.

Key results: ORR 96%, sCR/CR 74%, MRD negativity 95% (≤10-5), 12/18/24-month PFS of 82.1%/67.4%/61.7%, and 12/18/24-month OS of 94%/88%/83%. Safety was described as predictable and manageable: CRS 86% (mostly Grade 1), ICANS 8% (one Grade 3), and no delayed non-ICANS neurotoxicities observed to date.

Gilead (Nasdaq: GILD) presented Phase 1 data at ASH 2025 showing encouraging efficacy and tolerability for two investigational bicistronic CAR T therapies, KITE-753 and KITE-363, targeting CD19 and CD20 with dual co-stimulation.

Key data: in KITE-753 dose level 3 (0.2×10⁶ CAR T/kg) 11 of 14 CAR‑naïve patients (79%) had complete responses at median follow-up 2.9–4.0 months; across KITE-753 dose levels 14 of 20 CAR‑naïve patients achieved complete responses. KITE-363 showed durable remissions with median follow-up 17.5 months and >70% of evaluable complete responders at 12 months remaining in remission. No dose‑limiting toxicities reported.

Gilead Foundation (Nasdaq: GILD) committed over $3 million in Healing Hunger grants on November 24, 2025 to expand access to fresh food across California, North Carolina, New Jersey, Maryland, and Washington, D.C.

Grants fund 14 regional programs — mobile pantries, produce recovery, urban farming, and school distribution — with recipient targets such as 17 million pounds and 2.5 million pounds of food distributions in specific regions. The investment complements the Foundation's broader community giving and Gilead's recent 2025 U.S. investment announcement.